Omny-IRE data demonstrated the investigational OMNYPULSETM Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durabilit ...

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...

Kardium Inc., a private medical device company that's advancing the way the world treats atrial fibrillation (AF), announced late-breaking, one-year clinical trial results for its innovative pulsed ...

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...